← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Research (597)Review article (228)Early Study (Phase 1 or 2) (43)Case report (177)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (39)

Filter

Publications (1032)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treosulfan-Based Conditioning in Allogeneic Stem Cell Transplantation for Myelofibrosis: A Systematic Review. (2026/05/22) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)]. (2026/05/14) ♡
• High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort. (2026/05/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Myelofibrosis: watch and wait or treat?]. (2026/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. 99m Tc-FAPI Scintigraphy in Metastasis Workup of Sinonasal Rhabdomyosarcoma; Unveiling Diffuse Bone Marrow Involvement. (2026/05/01) ♡
• Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions. (2026/05/01) ♡
• Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. (2026/04/16) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study. (2026/04/04) ♡
• Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL. (2026/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Tailoring Intensity: A Perspective on Thiotepa, Busulfan, and Fludarabine (TBF) Conditioning for Acute Leukemias and Myeloproliferative Neoplasms. (2026/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. (2026/04/01) ♡
• Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm. (2026/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Myelofibrosis as a cause of non-cirrhotic portal hypertension]. (2026/04/01) ♡
• Pulmonary Complications Following Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Single-Center Retrospective Cohort Analysis. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current treatments, practical management, and emerging investigational therapies for myelofibrosis. (2026/03/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms. (2026/03/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm. (2026/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis. (2026/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Radiotherapy for extramedullary haematopoiesis of the mandibular mucosa secondary to myelofibrosis. (2026/02/24) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. When, which and how to switch: Navigating JAK inhibitors in myelofibrosis. (2026/02/01) ♡
• The Clinical Significance of CD371 Expression Detected by Flow Cytometry in Primary Myelofibrosis. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. (2026/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Germline heterozygous SH2B3 p.Glu78Lys variant: a three-patient case series with myeloproliferative neoplasms. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis. (2026/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Whipple's disease presenting with bone marrow findings mimicking prefibrotic myelofibrosis: A diagnostic pitfall. (2026/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Interferon alpha in myeloproliferative neoplasms: evidence and practical considerations for clinical care. (2026/02/01) ♡
• Predicting modelling for early diagnosis in early myeloproliferative neoplasms, not otherwise specified. Evidence from a machine learning study. (2026/01/26) ♡
• Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias. (2026/01/20) ♡
• Integrated one-pot RPA-CRISPR/Cas13a platform enables ultrasensitive and field-deployable JAK2 V617F detection for myeloproliferative neoplasm diagnosis. (2026/01/15) ♡
• Application of IVIM in the assessment of the spleen in patients with myelofibrosis. (2026/01/14) ♡
• Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. (2026/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis. (2026/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Low (0.1% to ≤ 1%) or Very Low (0.06% to < 0.1%) JAK2V617F Allele Burden in Routine Testing: Clinical Correlates and Clonal Trajectory. (2026/01/01) ♡
• Cytoreductive treatment differentially affects platelet size and cytoskeletal megakaryocyte organization during thrombopoiesis in myeloproliferative neoplasms. (2026/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene. (2026/01/01) ♡
• Platelets display immunophenotypic alterations and dysregulated transcriptomic signature in Philadelphia-negative myeloproliferative neoplasms. (2026/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. (2026/01/01) ♡
• Myelofibrosis as a Presenting Manifestation of Primary Hypertrophic Osteoarthropathy. (2026/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Disappearance of del (7q) with lenalidomide in myelofibrosis complicated with multiple myeloma]. (2026/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Genomic abnormalities in myeloproliferative neoplasms]. (2026/01/01) ♡
• Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel. (2025/12/30) ♡
• Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. (2025/12/28) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis. (2025/12/24) ♡
• Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms. (2025/12/24) ♡
• Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study. (2025/12/18) ♡
• Fedratinib reveals chemotherapeutic potential in esophageal squamous cell cancer. (2025/12/16) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Pediatric Essential Thrombocythemia: A Case of a JAK2-Mutated Adolescent With Microvascular Symptoms. (2025/12/16) ♡
• Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis. (2025/12/15) ♡
• Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders. (2025/12/15) ♡
• Nutritional factors and survival in a cohort of patients with myelofibrosis. (2025/12/15) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.